Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Degenerative Disc Disease I: Introduction01:27

Degenerative Disc Disease I: Introduction

29
Degenerative disc disease is a chronic condition in which intervertebral discs gradually lose structure and function. It is not infectious or autoimmune; rather, it results from age-related biochemical and mechanical changes, influenced by genetic, metabolic, and environmental factors.Structure and Function of DiscsThe spine contains 23 intervertebral discs that absorb load, distribute forces, maintain spacing, and allow flexibility. Each disc consists of a nucleus pulposus, a gel-like core...
29
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

1.3K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
1.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

3.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
3.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

991
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
991
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yoga-Nidra as a complementary therapy for reducing psychological distress and enhancing quality of life in cancer patients: A randomized controlled trial.

Complementary therapies in medicine·2025
Same author

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More.

South Asian journal of cancer·2025
Same author

Posterior Mediastinal Tumor Presenting with Compressive Myelopathy: Uncommon Site for a Rare Tumor.

Pediatric blood & cancer·2025
Same author

Cutaneous Adverse Effect of High-Dose Methotrexate.

Pediatric blood & cancer·2025
Same author

Robust Guidelines for the Management of HR+ Her2- EBC: Crucial Value of CanAssist Breast.

South Asian journal of cancer·2022
Same author

Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line.

Journal of biochemical and molecular toxicology·2022

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Denosumab: A comprehensive review.

Prasad Narayanan1

  • 1Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates.

South Asian Journal of Cancer
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

Denosumab, a RANKL inhibitor, effectively reduces bone resorption and skeletal-related events in advanced cancer patients. This review details its mechanism, clinical data, and future prospects for managing bone metastases.

Keywords:
Bone metastasisdenosumabskeletal-related events

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.4K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

16.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • Bone metastases cause debilitating skeletal-related events (SREs) in advanced cancer patients.
  • Increased osteoclast activity drives pathological bone resorption in bone metastases.
  • Tumor cells stimulate the RANK-RANKL pathway, crucial for osteoclast function.

Purpose of the Study:

  • To provide a comprehensive overview of Denosumab for managing bone metastases.
  • To elucidate Denosumab's mechanism of action in inhibiting osteoclast activity.
  • To review clinical trial data, adverse effects, and future challenges associated with Denosumab therapy.

Main Methods:

  • Review of existing literature on Denosumab and RANKL inhibition.
  • Analysis of clinical trial data regarding efficacy and safety.
  • Examination of Denosumab's pharmacological properties and mechanism of action.

Main Results:

  • Denosumab inhibits the RANKL pathway, reducing osteoclast formation, activation, and survival.
  • This inhibition leads to decreased bone resorption and mitigation of SREs.
  • Clinical trials demonstrate Denosumab's efficacy in reducing cancer-induced bone destruction.

Conclusions:

  • Denosumab is a targeted therapy for inhibiting RANKL, crucial in managing bone metastases.
  • The drug offers a significant therapeutic option for reducing skeletal-related events in cancer patients.
  • Further research is needed to address future challenges and optimize Denosumab's use.